Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alectinib + ceritinib
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alectinib and ceritinib are both second-generation anaplastic lymphoma kinase (ALK) inhibitors used for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Both drugs were developed to overcome resistance to crizotinib, the first-generation ALK inhibitor. Alectinib is approximately 20 times more potent than crizotinib in inhibiting ALK, while ceritinib has shown activity against common crizotinib-resistant mutations including L1196M and G1269A. Both medications have demonstrated efficacy in patients with brain metastases due to their superior brain penetration compared to crizotinib. These drugs are not typically administered together but rather used as alternative treatment options.
- Brand names
- Alecensa + Zykadia
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)
Beyond the preview
Go deeper on alectinib + ceritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alectinib + ceritinib.